Trial Profile
A Phase II Study of Olaparib Plus Cediranib in Combination With Standard Therapy for Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Oct 2023
Price :
$35
*
At a glance
- Drugs Cediranib (Primary) ; Olaparib (Primary) ; Carboplatin; Cisplatin; Etoposide
- Indications Small cell lung cancer
- Focus Therapeutic Use
- 18 Mar 2020 Status changed from suspended to discontinued.
- 22 Jun 2018 Status changed from recruiting to suspended.
- 02 May 2018 Status changed from suspended to recruiting.